Although the types of cancer are vastly different, each of the awardees is seeking better, more targeted, and less toxic ways to treat cancer in children. CCF is proud to support these innovators as we push ahead to a world of cancer treatment being unique to the individual and eradicating the cancer cells exclusively, without the long, devastating and toxic treatments children have faced for the last forty years.

Each year, research grant proposals are reviewed by an independently-appointed review panel of three pediatric oncology researchers from institutions outside of the District of Columbia, Maryland and Northern Virginia with no connection to local applicants. The proposals are ranked on merit and established science standards. Typical research grants are $75,000 and for one year, but funding levels vary depending on funds raised from the community and the number of applications received.

2023 Grant Awards

Chris Albanese, Ph.D.

Georgetown University

Medulloblastoma

Curt Civin, M.D.

University of Maryland

Acute Myeloid Leukemia, ALL, and infant Leukemias

Charles Eberhart, M.D., Ph.D.

Johns Hopkins Medicine

Retinoblastoma

Yiouli P. Ktena, M.D.

Johns Hopkins Medicine,
NextGen Awardee

Leukemia and Lymphoma

Gary Kupfer, M.D.

Georgetown University

Head and neck cancers

Nicolas Llosa, M.D.

Johns Hopkins Medicine

Rhabdomyosarcoma

Chase McCann, Ph.D.

Children’s National Hospital

Multiple (Hematologic, solid, Brain)

Anandani Nellan, M.D.

National Cancer Institute

Glioblastoma/Central nervous system

James Cronk, M.D.

National Cancer Institute

Glioblastoma/Central nervous system

Patience Odeniyide, M.D., Ph.D.

Johns Hopkins Medicine

Rhabdomyosarcoma

Haneen Shalabi, D.O.

National Cancer Institute

B-cell-ALL, B-cell Lymphoma

Aykut Üren, M.D.

Georgetown University

Osteosarcoma